Roy A. Fox
Brighton, ENG BN19RH, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
Journal: European journal of medicinal chemistry
Published: August 15, 2024
ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 05, 2024
Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A.
Journal: Frontiers in pharmacology
Published: January 11, 2023
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
Journal: American journal of respiratory and critical care medicine
Published: January 04, 2020
Genome-wide analysis of canine oral malignant melanoma metastasis-associated gene expression.
Journal: Scientific reports
Published: November 07, 2018
Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.
Journal: Frontiers in pharmacology
Published: March 08, 2017
Proposed model of integrated care to improve health outcomes for individuals with multimorbidities.
Journal: Patient preference and adherence
Published: October 24, 2012
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Journal: American journal of respiratory and critical care medicine
Published: October 23, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026